News
02-21-2015, 12:00 AM
Palbociclib, an investigational oral medication that works by blocking molecules responsible for cancer cell growth, is well tolerated and extends progression-free survival (PFS) in newly diagnosed, advanced breast cancer patients, including those whose disease has stopped responding to traditional endocrine treatments.
More... (http://www.news-medical.net/news/20150221/Palbociclib-extends-progression-free-survival-in-advanced-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20150221/Palbociclib-extends-progression-free-survival-in-advanced-breast-cancer-patients.aspx)